Stocks · News reference
Enlivex reported positive 12-month results from its Phase IIa trial of Allocetra™ in patients with moderate to severe knee osteoarthritis, showing a statistically significant treatment benefit compared to placebo.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Enlivex has reached a significant milestone in its Phase 2b clinical trial, with 135 of the planned 182 patients randomized and receiving their first injection of Allocetra.
Enlivex Ltd. announced it received a delisting notification from Nasdaq due to its share price falling below the minimum bid requirement and plans to appeal the decision.
Enlivex Ltd. has announced a 1-for-16 reverse split of its ordinary shares, which is scheduled to become effective on October 27, 2026.
Non-clinical R&D activities to be wound down; resources to be focused on executing the Phase 2b trialWorkforce reduced by approximately 60%; management and CEO salaries reducedPlan designed to substantially reduce
S&P 500 to open higher? Polymarket odds reach 70% as Wall Street digests September jobs, 24-year high Treasury yields, and Iran sanctions.